BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 7, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: BioWorld 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science, Patents

BioWorld Science, Patents
BioWorld Science, Patents RSS Feed RSS

Neurology/psychiatric

Chengdu Kanghong Pharmaceutical patents LRRK2 inhibitors

Jan. 23, 2026
Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, glaucoma, inflammatory bowel disease, multiple sclerosis, neurodegeneration, psoriasis and rheumatoid arthritis, among others.
Read More
Respiratory

Beijing Tide Pharmaceutical divulges new cathepsin C inhibitors

Jan. 23, 2026
Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.
Read More
Cancer

Acerand Therapeutics discovers new CYP11A1 inhibitors

Jan. 23, 2026
Acerand Therapeutics (Hong Kong) Ltd. has divulged new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Bio-Thera Solutions identifies new HER2-targeted antibody-drug conjugates

Jan. 23, 2026
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.
Read More
Infection

Centre Hospitalier Regional Universitaire de Lille divulges new 3CLpro inhibitors

Jan. 23, 2026
Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Cancer

Sunshine Lake Pharma divulges new PKMYT1 inhibitors

Jan. 22, 2026
Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.
Read More
Cancer

Beyang Therapeutics discovers salts of VEGFR inhibitors

Jan. 22, 2026
Beyang Therapeutics Co. Ltd. has divulged salts of vascular endothelial growth factor receptor (VEGFR) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory, neurodegeneration, cardiovascular, metabolic and eye disorders.
Read More
Cancer

Shanghai Qingrun Pharmaceutical Technology synthesizes new GTPase KRAS mutant inhibitors

Jan. 22, 2026
Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has discovered new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.
Read More
Immuno-oncology

Lunan New Time Biotechnical reports new camptothecin derivatives and their ADCs

Jan. 22, 2026
Lunan New Time Biotechnical Co. Ltd. has identified new camptothecin derivatives and their antibody-drug conjugates reported to be useful for the treatment of cancer.
Read More
Inflammatory

Rezubio Pharmaceuticals discloses new drug conjugates to treat fibrosis

Jan. 22, 2026
Rezubio Pharmaceuticals Co. Ltd. has reported new drug conjugates comprising lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists covalently linked to a hydrophilic moiety through a linker reported to be useful for the treatment of fibrosis.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 3712 3713 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 6, 2025.
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Brain illustrated with pills

    Serotonin receptor modulators for the treatment of OUD

    BioWorld Science
    Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
  • Liver anatomy illustration

    KLF15 shows potential as marker, target for cholangiocarcinoma

    BioWorld Science
    Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing